Abstract
To be an effective medicine a drug has to possess many attributes to ensure target potency and specificity, lack of toxicity, bioavailability and duration of action. Discovering a compound with these properties is invariably an evolutionary process. Fragment based drug discovery sets out to identify a starting compound by screening a library of small molecules representing fragments which cover the chemical space of drug like matter. Fragment based screening is increasingly used in the pharmaceutical industry in the early stages of lead identification and optimization. We will provide an introduction into this approach and discuss a number of examples which show how fragment based drug discovery has been used in the discovery of starting points for drug discovery programs and in their optimization.
Keywords: Fragment-based drug discovery, screening, medicinal chemistry
Mini-Reviews in Medicinal Chemistry
Title: From Fragment Screening to Potent Binders: Strategies for Fragment-to-Lead Evolution
Volume: 9 Issue: 8
Author(s): Krystian Eitner and Uwe Koch
Affiliation:
Keywords: Fragment-based drug discovery, screening, medicinal chemistry
Abstract: To be an effective medicine a drug has to possess many attributes to ensure target potency and specificity, lack of toxicity, bioavailability and duration of action. Discovering a compound with these properties is invariably an evolutionary process. Fragment based drug discovery sets out to identify a starting compound by screening a library of small molecules representing fragments which cover the chemical space of drug like matter. Fragment based screening is increasingly used in the pharmaceutical industry in the early stages of lead identification and optimization. We will provide an introduction into this approach and discuss a number of examples which show how fragment based drug discovery has been used in the discovery of starting points for drug discovery programs and in their optimization.
Export Options
About this article
Cite this article as:
Eitner Krystian and Koch Uwe, From Fragment Screening to Potent Binders: Strategies for Fragment-to-Lead Evolution, Mini-Reviews in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/138955709788681645
DOI https://dx.doi.org/10.2174/138955709788681645 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Role of Indoleamine 2,3-Dioxygenase in Antimicrobial Defence and Immuno-Regulation: Tryptophan Depletion Versus Production of Toxic Kynurenines
Current Drug Metabolism Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design COPD: Optimal Current Treatment Strategies and Promising New Therapeutic Modalities
Current Respiratory Medicine Reviews Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology Emerging Role of CD44 Receptor as a Potential Target in Disease Diagnosis: A Patent Review
Recent Patents on Inflammation & Allergy Drug Discovery Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Circulating Insulin-like Growth Factor-1 Levels in Patients with Rheumatoid Arthritis: A Meta-analysis
Current Pharmaceutical Design Assortment of Human Amniotic Membrane and Curcumin: a Potential Therapeutic Strategy for Burn Wound Healing
Current Drug Therapy Pro-inflammatory Mediators and Oxidative Stress: Therapeutic Markers for Recurrent Angina Pectoris after Coronary Artery Stenting in Elderly Patients
Current Vascular Pharmacology Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Plant Proteinases and Inhibitors: An Overview of Biological Function and Pharmacological Activity
Current Protein & Peptide Science Cytomegalovirus Prophylaxis in Solid Organ Transplantation
Current Medicinal Chemistry Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.
Current Molecular Medicine Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it
Current Rheumatology Reviews Old Versus New Anticoagulants: Focus on Pharmacology
Recent Patents on Cardiovascular Drug Discovery Immune Checkpoint Inhibitors in AML-A New Frontier
Current Cancer Drug Targets